Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

About this trial

This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 1,346 patients with Stanford Type A aortic dissection, conducted between 2025 and 2028. Participants will receive either ketorolac (60 mg intramuscularly \[IM\] within 6 hours before surgery and 30 mg im twice daily(at 6:00 AM and 6:00 PM, respectively for two days postoperatively or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ketorolac

    Drug

    patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection within 6 hours before surgery followed by 30mg im twice daily(at 6:00 AM and 6:00 PM, respectively )for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.

  • 0.9 % saline

    Drug

    0.9% saline

Treatment groups

1,346 Participants
are divided into 2 treatment groups
Group A: Ketorolac GroupExperimental treatment 1 intervention
Group B: Placebo GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Primary endpoints

In-hospital mortality and the occurrence of organ malperfusion syndrome (including myocardial ischemia, stroke, lower limb paralysis, acute abdominal pain, renal failure requiring temporary dialysis, or limb ischemia) during the hospitalization.

Time frame
Continuous intervention for 3 days after admission, with a 1-year follow-up.

Secondary outcomes

1

erythrocyte sedimentation rate (ESR)

erythrocyte sedimentation rate (ESR), an indicator of systemic inflammation that reflects the rate at which red blood cells settle in a vertical tube over a specified period. Elevated ESR levels may suggest ongoing inflammatory responses, infection, or tissue injury

Time frame
Preoperative and postoperative assessments on days 1, 3, 5, 7, 30, and 90
2

The perioperative use of opioids

The perioperative use of opioids such as fentanyl and remifentanil is also assessed

Time frame
perioperative
3

C-reactive protein (CRP)

C-reactive protein (CRP), an acute-phase protein synthesized by the liver that rises rapidly in response to infection, inflammation, or tissue injury. CRP serves as a sensitive biomarker of systemic inflammatory response and will be used to assess the perioperative inflammatory status in patients with Stanford Type A aortic dissection.

Time frame
Preoperative and postoperative assessments on days 1, 3, 5, 7, 30, and 90
4

interleukin-6 (IL-6)

interleukin-6 (IL-6), a pro-inflammatory cytokine produced by various cells in response to tissue injury, infection, or stress. IL-6 plays a key role in the acute-phase inflammatory response and is closely associated with the severity of systemic inflammation.

Time frame
Preoperative and postoperative assessments on days 1, 3, 5, 7, 30, and 90

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Lead sponsor

Guangdong Provincial People's Hospital

Collaborator

Huai'an First People's Hospital

Collaborator

Shandong Provincial Hospital

Collaborator

First Affiliated Hospital of Harbin Medical University

Collaborator

The Second Affiliated Hospital of Harbin Medical University

Collaborator

The First Affiliated Hospital of Shihezi University

Collaborator

Xinhua Hospital of Ili Kazak Autonomous Prefecture

Collaborator

Henan Provincial Chest Hospital

Collaborator

First Affiliated Hospital of Zhejiang University

Collaborator